Boston Scientific Corp. (BSX)
Boston Scientific Corporation (BSX) is a global medical device company specializing in innovative healthcare solutions. Founded in 1979, it develops and manufactures devices for cardiovascular, respiratory, digestive, and other medical conditions, focusing on minimally invasive procedures and improving patient outcomes.
Company News
The global neuromodulation market is projected to grow at a 9.27% CAGR, reaching $9.32 billion by 2032, driven by rising chronic disorders, technological innovations, and demand for non-invasive treatments, despite challenges like high device costs and regulatory constraints.
Three biotech companies - Boston Scientific, Arcutis Biotherapeutics, and Tarsus Pharmaceuticals - show promising developments in medical devices and drug treatments, with potential for significant investor returns.
Boston Scientific reported 386 injuries and 16 deaths related to calcified defibrillator leads with potential shock delivery failures. The FDA is reviewing the high-risk device issue involving ENDOTAK RELIANCE leads coated with ePTFE.
Baxter International Inc. reported better-than-expected Q2 2024 earnings, with adjusted EPS of 68 cents beating the consensus estimate. Revenue also topped expectations, driven by growth across the company's business segments. The company provided positive guidance for Q3 and full-year 2024.
The company is planning to file for regulatory approval of a label expansion for Ozempic in the U.S. and European Union in 2024.
